You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 1, January 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Epidemiology and Biostatistics
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Immunology
 •Immunologic Disorders
 •Infectious Diseases
 •HIV/AIDS
 •Alert me on articles by topic

Visual Loss in Patients With Cytomegalovirus Retinitis and Acquired Immunodeficiency Syndrome Before Widespread Availability of Highly Active Antiretroviral Therapy

Janet T. Holbrook, PhD, MPH; Douglas A. Jabs, MD, MBA; David V. Weinberg, MD; Richard Alan Lewis, MD, MS; Matthew D. Davis, MD; Dorothy Friedberg, MD, PhD; for the Studies of Ocular Complications of AIDS (SOCA) Research Group

Arch Ophthalmol. 2003;121:99-107.

Objective  To evaluate rates and causes of visual loss among patients with acquired immunodeficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis before widespread availability of highly active antiretroviral therapy (HAART).

Methods  Data from 681 patients with AIDS and newly diagnosed or relapsed CMV retinitis who enrolled in 3 clinical trials conducted by the Studies of Ocular Complications of AIDS (SOCA) Research Group (between 1990 and 1996) were combined to evaluate the rates and causes of visual loss. Visual acuity and visual field (Goldmann visual fields) losses were evaluated.

Results  The rates of visual loss in eyes with CMV retinitis were substantial in all 3 clinical trials, ranging from 51.7 to 97.7 events per 100 eye-years for loss of visual acuity to worse than 20/40 and 18.9 to 49.1 events per 100 eye-years for loss of visual acuity to 20/200 or worse. The 2 major causes of visual loss were retinitis, involving either the macula or the optic nerve, and retinal detachment. After 1992, visual outcomes improved significantly. Antiretroviral therapy was associated with a 30% reduction in the risk of visual acuity loss (relative risk, 0.70; P = .02).

Conclusions  In the pre-HAART era, visual morbidity was substantial. However, there was a secular trend for improved outcomes. The principal causes of visual loss were CMV involvement of the posterior retina and retinal detachment.


From the Center for Clinical Trials, Bloomberg School of Public Health (Drs Holbrook and Jabs), and the Departments of Ophthalmology and Medicine, School of Medicine (Dr Jabs), Johns Hopkins University, Baltimore, Md; the Department of Ophthalmology, Northwestern University, Evanston, Ill (Dr Weinberg); the Department of Ophthalmology and Cullen Eye Institute, Baylor College of Medicine, Houston, Tex (Dr Lewis); the Fundus Photograph Reading Center, Department of Ophthalmology, University of Wisconsin, Madison (Dr Davis); and the Department of Ophthalmology, New York University, New York (Dr Friedberg).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.